The history of juvenile myoclonic epilepsy |
| |
| Affiliation: | 1. Centre Saint Paul-Hôpital Henri Gastaut, Marseille, France;2. Epilepsy Unit, Gui de Chauliac Hospital, Montpellier, France;1. Institute of Child Neurology, Schneider Children''s Medical Center of Israel, Petach Tikva, Israel;2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;3. Department of Neurology, Wolfson Medical Center, Holon, Israel;4. Neuropediatric Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;5. Pediatric Neurology and Developmental Unit, Loewenstein Rehabilitation Hospital, Raanana, Israel;6. Pediatric Neurology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel;7. Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel;8. Genetic Institute, Emek Medical Center, Afula, Israel;9. Genetics Unit, Schneider Children''s Medical Center of Israel, Petach Tikva, Israel;10. Department of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, MN, USA;1. University of Tampere, Faculty of Medicine and Life Sciences, FI-33014 Tampere, Finland;2. Tampere University Hospital, Department of Psychiatry, FI-33014 Tampere, Finland;3. Seinäjoki Hospital District, Department of Psychiatry, Huhtalantie 53, 60220 Seinäjoki, Finland |
| |
| Abstract: | Juvenile myoclonic epilepsy (JME) has been the subject of intensive research over the past 25 years. It was discovered stepwise in Switzerland and France in the 19th century, adequately described in Germany and Uruguay in the 1950s, and rediscovered in North America in the early 1980s. Juvenile myoclonic epilepsy represents the most common idiopathic epilepsy syndrome. As a tribute to the primary author of the first extensive and detailed clinical description of JME, it is also called the Janz syndrome. Juvenile myoclonic epilepsy is an archetypical epileptic syndrome, with a fairly homogenous presentation and a still largely unknown etiology. Its clinical spectrum now includes cognitive and psychiatric symptoms as significant copathologies, and the elucidation of its probably multiple genetic mechanisms is an ongoing process. Juvenile myoclonic epilepsy may not qualify as a “benign” epilepsy, but seizures in most patients can be managed adequately and patients will not suffer severe limitations in their lifetime expectations.This article is part of a supplemental special issue entitled Juvenile Myoclonic Epilepsy: What is it Really? |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
